{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:16:41Z","timestamp":1773850601003,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T00:00:00Z","timestamp":1241481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00280-009-1009-6","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T17:18:15Z","timestamp":1241457495000},"page":"107-112","source":"Crossref","is-referenced-by-count":18,"title":["Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. I.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hotchkiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. M.","family":"Ferencz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,5]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hyne","year":"2005","unstructured":"Hyne NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341\u2013354","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1009_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccr.2008.03.010","volume":"13","author":"DJ Leahy","year":"2008","unstructured":"Leahy DJ (2008) A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell 13(4):365\u2013373","journal-title":"Cancer Cell"},{"issue":"6","key":"1009_CR3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clinthera.2005.06.003","volume":"27","author":"SF Wong","year":"2005","unstructured":"Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27(6):684\u2013694","journal-title":"Clin Ther"},{"key":"1009_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","volume":"18","author":"M Cohenuram","year":"2007","unstructured":"Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18:7\u201315","journal-title":"Anticancer Drugs"},{"key":"1009_CR5","unstructured":"Erbitux (cetuximab) [package insert] 2005 ImClone Systems Inc\/Bristol-Myers Squibb Co, New York"},{"issue":"4","key":"1009_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy, cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337\u2013345","journal-title":"N Engl J Med"},{"issue":"7","key":"1009_CR7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201\u20131208","journal-title":"J Clin Oncol"},{"issue":"6","key":"1009_CR8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head, neck. N Engl J Med 354(6):567\u2013578","journal-title":"N Engl J Med"},{"issue":"1","key":"1009_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","volume":"6","author":"TB Gibson","year":"2006","unstructured":"Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6(1):29\u201331","journal-title":"Clin Colorectal Cancer"},{"issue":"13","key":"1009_CR10","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Cutsem Van","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658\u20131664","journal-title":"J Clin Oncol"},{"issue":"1","key":"1009_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdm399","volume":"19","author":"E Cutsem Van","year":"2008","unstructured":"Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M (2008) An open-label, single-arm study assessing safety, efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19(1):92\u201398","journal-title":"Ann Oncol"},{"key":"1009_CR12","doi-asserted-by":"crossref","unstructured":"Vectibix (panitumumab) [package insert] 2006 Agmen, Thousand Oaks, California","DOI":"10.3833\/pdr.v2006i78.424"},{"issue":"6","key":"1009_CR13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-008-0831-6","volume":"63","author":"MW Saif","year":"2009","unstructured":"Saif MW, Peccerillo J, Potter V (2009) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 63(6):1017\u20131022","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1009_CR14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3816\/CCC.2007.n.019","volume":"6","author":"J Heun","year":"2007","unstructured":"Heun J, Holen K (2007) Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 6(7):529\u2013531","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"1009_CR15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/annonc\/mdm130","volume":"18","author":"D Helbling","year":"2007","unstructured":"Helbling D, Borner M (2007) Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 18(5):963\u2013964","journal-title":"Ann Oncol"},{"issue":"8","key":"1009_CR16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/02841860600871764","volume":"45","author":"DL Nielsen","year":"2006","unstructured":"Nielsen DL, Pfeiffer P, Jensen BV (2006) Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab, two case reports. Acta Oncol 45(8):1137\u20131138","journal-title":"Acta Oncol"},{"issue":"4","key":"1009_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00520-006-0159-x","volume":"15","author":"B Melichar","year":"2007","unstructured":"Melichar B, Cerman J Jr, Mal\u00edrov\u00e1 E (2007) Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer 15(4):445\u2013449","journal-title":"Support Care Cancer"},{"issue":"9","key":"1009_CR18","first-page":"451","volume":"5","author":"SP Kang","year":"2007","unstructured":"Kang SP, Saif MW (2007) Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer\u2014identification, prevention, and management. J Support Oncol 5(9):451\u2013457","journal-title":"J Support Oncol"},{"issue":"5 Suppl 14","key":"1009_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/sonc.2002.35648","volume":"29","author":"MN Needle","year":"2002","unstructured":"Needle MN (2002) Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 29(5 Suppl 14):55\u201360","journal-title":"Semin Oncol"},{"issue":"4","key":"1009_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","volume":"115","author":"LE Kolk van der","year":"2001","unstructured":"van der Kolk LE, Grillo-L\u00f3pez AJ, Baars JW, Hack CE, van Oers MH (2001) Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115(4):807\u2013811","journal-title":"Br J Haematol"},{"issue":"3","key":"1009_CR21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects, rapid blood tumor clearance. J Clin Oncol 17(3):791\u2013795","journal-title":"J Clin Oncol"},{"key":"1009_CR22","unstructured":"National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0. (CTCAE)"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1009-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1009-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1009-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:58Z","timestamp":1559023618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1009-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1009-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,5]]}}}